-
Scipher Medicine Announces $82 Million Financing -
Addressing wasted healthcare dollars and ineffective prescriptions -
Reduce Wasted Spend While Significantly Improving Clinical Outcomes -
Understanding protein interaction to optimize drug discovery -
WellDyne Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care -
Scipher Medicine Brings Precision Medicine Platform to Patient-Centered MIT Initiative -
New Study Demonstrates Clinical Utility of PrismRA Test in Guiding Therapy Selection for Rheumatoid Arthritis Patients -
Mariann Byerwalter joins Scipher Medicine’s Board of Advisors -
18th U.S. Surgeon General Joins Scipher Medicine -
Scipher Medicine and Ambry Genetics Partner to Bring Precision Medicine Test for Rheumatoid Arthritis to Market -
New Strategy for Avoiding Waste and Improving Response for Highest Cost Therapies in Rheumatoid Arthritis -
Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease -
Scipher Medicine Announces Publication of Clinical Study Validating PrismRA, a Blood Test Predicting Non-Response to TNF Inhibitor Therapies in Patients with Rheumatoid Arthritis -
Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients -
Scipher Medicine Welcomes Jerry Conway, Appointed Senior Vice President of Market Access